<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations of lung cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations of lung cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations of lung cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David E Midthun, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rogerio C Lilenbaum, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Worldwide, lung cancer occurred in approximately 2.2 million patients in 2020 and caused an estimated 1.8 million deaths [
         <a href="#rid1">
          1
         </a>
         ]. In the United States, lung cancer occurs in approximately 235,000 patients and causes over 130,000 deaths annually [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Around 1953, lung cancer became the most common cause of cancer deaths in men, and in 1985, it became the leading cause of cancer deaths in women. However, lung cancer deaths have begun to decline in both men and women, reflecting a decrease in smoking. (See
         <a class="medical medical_review" href="/z/d/html/1431.html" rel="external">
          "Females and lung cancer"
         </a>
         .)
        </p>
        <p>
         The majority of patients with lung cancer have advanced disease at clinical presentation. This may reflect the aggressive biology of the disease and the frequent absence of symptoms until locally advanced or metastatic disease is present. High-risk patients may be diagnosed while asymptomatic through screening with low-dose computed tomography.
        </p>
        <p>
         Symptoms may result from local effects of the tumor, from regional or distant spread, or from distant effects not related to metastases (paraneoplastic syndromes). Approximately three-fourths of nonscreened patients have one or more symptoms at the time of diagnosis. One study noted that the most common symptoms at presentation were cough (55 percent), dyspnea (45 percent), pain (38 percent), and weight loss (36 percent)  (
         <a class="graphic graphic_table graphicRef76229" href="/z/d/graphic/76229.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         This discussion will present the clinical manifestations of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Screening and risk factors for lung cancer, as well as an overview of the initial evaluation, diagnosis, treatment, and prognosis of lung cancer are presented separately. A more detailed discussion on risk factors is also presented elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">
          "Screening for lung cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">
          "Cigarette smoking and other possible risk factors for lung cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4639.html" rel="external">
          "Overview of the initial treatment and prognosis of lung cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          INTRATHORACIC CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are a wide range of symptoms due to the intrathoracic effects of the cancer, the most common of which are cough, hemoptysis, chest pain, and dyspnea.
        </p>
        <p class="headingAnchor" id="H355281935">
         <span class="h2">
          Cough
         </span>
         <span class="headingEndMark">
          —
         </span>
         The new onset of cough in a smoker or former smoker should raise suspicion for lung cancer.
        </p>
        <p>
         Cough is present in 50 to 75 percent of lung cancer patients at presentation and occurs most frequently in patients with squamous cell and small cell carcinomas because of their tendency to involve central airways [
         <a href="#rid3">
          3-5
         </a>
         ]. Bronchorrhea or cough productive of large volumes of thin, mucoid secretions may be a feature of mucinous adenocarcinoma and usually indicates advanced disease. Both NSCLC and SCLC may cause a postobstructive pneumonia. However, bronchiectasis from bronchial obstruction is uncommon because lung cancer usually progresses too rapidly for bronchiectasis to develop. By contrast, slow-growing neoplasms such as carcinoid tumor or hamartoma are more likely to present with bronchiectasis. (See
         <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">
          "Causes and epidemiology of subacute and chronic cough in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4883.html" rel="external">
          "Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">
          "Pathology of lung malignancies", section on 'Adenocarcinoma'
         </a>
         .)
        </p>
        <p>
         The presenting symptom has some bearing on prognosis; a series of 3800 patients with lung cancer showed that patients presenting with cough had a better prognosis than those presenting with other symptoms [
         <a href="#rid6">
          6
         </a>
         ]. Presentation with cough appeared to correlate with earlier stage, and possibly serendipitous discovery of the cancer.
        </p>
        <p class="headingAnchor" id="H355281942">
         <span class="h2">
          Hemoptysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a patient with hemoptysis, the likelihood of lung cancer varies from 3 to 34 percent in different series depending upon the patient's age and smoking history [
         <a href="#rid7">
          7
         </a>
         ]. In smokers with hemoptysis and a nonsuspicious or normal chest radiograph, bronchoscopy will diagnose lung cancer in approximately 5 percent of cases [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4333.html" rel="external">
          "Evaluation of nonlife-threatening hemoptysis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis"
         </a>
         .)
        </p>
        <p>
         Hemoptysis is reported by 15 to 30 percent of patients who are diagnosed with lung cancer, although bronchitis is the most common cause of this symptom [
         <a href="#rid3">
          3-5
         </a>
         ]. Any amount of hemoptysis can be alarming to the patient, and large volumes of hemoptysis may cause asphyxia.
        </p>
        <p class="headingAnchor" id="H355281949">
         <span class="h2">
          Chest pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest pain is present in approximately 20 to 40 percent of patients presenting with lung cancer [
         <a href="#rid3">
          3,5,9
         </a>
         ]. It can be quite variable in character and is more common in younger compared with older patients. Pain is typically present on the same side of the chest as the primary tumor. Dull, aching, persistent pain may occur from mediastinal, pleural, or chest wall extension, but the presence of pain does not necessarily preclude resectability. Although pleuritic pain may be the result of direct pleural involvement, obstructive pneumonitis or a pulmonary embolus related to a hypercoagulable state may also cause chest pain.
        </p>
        <p class="headingAnchor" id="H355281956">
         <span class="h2">
          Dyspnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Shortness of breath is a common symptom in patients with lung cancer at the time of diagnosis, occurring in approximately 25 to 40 percent of cases [
         <a href="#rid3">
          3-5
         </a>
         ]. Dyspnea may be due to extrinsic or intraluminal airway obstruction, obstructive pneumonitis or atelectasis, lymphangitic tumor spread, tumor emboli, pneumothorax, pleural effusion, or pericardial effusion with tamponade. Partial obstruction of a bronchus may cause a localized wheeze, heard by the patient or by the clinician on auscultation, while stridor can result from obstruction of the trachea.
        </p>
        <p>
         Pulmonary function testing may be useful in a patient with dyspnea due to lung cancer, as it may show flattening of the expiratory and/or inspiratory flow-volume loop from presence of tumor in the trachea itself  (
         <a class="graphic graphic_figure graphicRef57161" href="/z/d/graphic/57161.html" rel="external">
          figure 1
         </a>
         ), from extrinsic compression, or from vocal cord paralysis. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
         Unilateral paralysis of the diaphragm may be due to damage of the phrenic nerve  (
         <a class="graphic graphic_diagnosticimage graphicRef75001" href="/z/d/graphic/75001.html" rel="external">
          image 1
         </a>
         ). Patients may be asymptomatic or report shortness of breath. In one series, lung cancer was the most common neoplasm affecting the phrenic nerve, although malignancy accounted for only 4 percent of patients presenting with diaphragmatic paralysis [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5115.html" rel="external">
          "Diagnostic evaluation of adults with bilateral diaphragm paralysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355281963">
         <span class="h2">
          Hoarseness
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of persistent hoarseness in a smoker includes both laryngeal cancer and lung cancer. In patients with lung cancer, this is due to malignancy involving the recurrent laryngeal nerve along its course under the arch of the aorta and back to the larynx [
         <a href="#rid11">
          11,12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6851.html" rel="external">
          "Hoarseness in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355282026">
         <span class="h2">
          Pleural involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pleural involvement can manifest as pleural thickening or nodularity without pleural effusion  (
         <a class="graphic graphic_diagnosticimage graphicRef68407" href="/z/d/graphic/68407.html" rel="external">
          image 2
         </a>
         ) or as malignant pleural effusion.
        </p>
        <p>
         Although malignant pleural effusions can cause dyspnea and cough, approximately one-fourth of patients who have lung cancer and pleural metastases are asymptomatic [
         <a href="#rid13">
          13
         </a>
         ]. Although a malignant pleural effusion precludes curative resection, not all pleural effusions in patients with lung cancer are malignant. A benign pleural effusion may occur in a patient with a resectable lung cancer due to lymphatic obstruction, postobstructive pneumonitis, or atelectasis. In a patient with a pleural effusion, the presence of tumor needs to be confirmed or excluded so that a chance for curative resection is not missed. Series report that 5 to 14 percent of patients with NSCLC and an ipsilateral pleural effusion have resectable disease [
         <a href="#rid14">
          14,15
         </a>
         ]. Surgical thoracoscopy or medical pleuroscopy should follow two negative pleural fluid cytologies to further evaluate the pleural space prior to surgical resection of a primary lesion.
        </p>
        <p>
         Malignant effusions are typically exudates and may be serous, serosanguineous, or grossly bloody. The yield of pleural fluid cytology after a single thoracentesis in patients with documented pleural involvement is approximately 60 percent; the yield rises to approximately 75 percent with a second thoracentesis, and there is little additional gain with additional thoracentesis [
         <a href="#rid16">
          16,17
         </a>
         ]. Closed pleural biopsy adds little to the yield of cytologic examination. In a patient with a suspected malignancy, repeat pleural fluid cytology with or without pleural biopsy is appropriate if the initial study is negative. A prospective series evaluated cytologic yield from pleural fluid aliquots of 10 mL, 60 mL, and ≥150 mL [
         <a href="#rid18">
          18
         </a>
         ]. The sensitivity for diagnosing malignancy in the pleural fluid was lower for volumes of 10 mL compared with the higher volumes. Medical pleuroscopy has a sensitivity of &gt;90 percent for malignancy and may be considered for patients with pleural effusions and suspected malignancy who are cytology negative  (
         <a class="graphic graphic_picture graphicRef99550" href="/z/d/graphic/99550.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">
          "Pleural fluid analysis in adults with a pleural effusion"
         </a>
         .)
        </p>
        <p>
         During the course of their disease, approximately 10 to 15 percent of patients who have lung cancer will have a malignant pleural effusion  (
         <a class="graphic graphic_diagnosticimage graphicRef81680 graphicRef56176" href="/z/d/graphic/81680.html" rel="external">
          image 3A-B
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ]. The management of patients with malignant pleural effusions is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6700.html" rel="external">
          "Management of malignant pleural effusions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355282033">
         <span class="h2">
          Superior vena cava syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obstruction of the superior vena cava (SVC) causes symptoms that commonly include a sensation of fullness in the head and dyspnea. Cough, pain, and dysphagia are less frequent. Physical findings include dilated neck veins; a prominent venous pattern on the chest; edema of the face, neck, and upper extremities; and a plethoric appearance  (
         <a class="graphic graphic_picture graphicRef81445" href="/z/d/graphic/81445.html" rel="external">
          picture 2
         </a>
         ). The chest radiograph typically shows widening of the mediastinum or a right hilar mass. Computed tomography can often identify the cause, level of obstruction, and extent of collateral venous drainage [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         The SVC syndrome is more common in patients with SCLC than NSCLC. For most patients who have SVC syndrome secondary to lung cancer, the symptoms resolve after treatment of the mediastinal tumor. The pathophysiology and treatment options for the management of patients with SVC syndrome are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355282040">
         <span class="h2">
          Pancoast syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung cancers arising in the superior sulcus cause a characteristic Pancoast syndrome manifested by pain (usually in the shoulder, and less commonly in the arm, scapula, and fingers), Horner syndrome, bony destruction, and atrophy of hand muscles. (See
         <a class="medical medical_review" href="/z/d/html/5249.html" rel="external">
          "Horner syndrome"
         </a>
         .)
        </p>
        <p>
         Pancoast syndrome is most commonly caused by NSCLC (typically squamous cell) and only rarely by SCLC  (
         <a class="graphic graphic_diagnosticimage graphicRef55842 graphicRef81147" href="/z/d/graphic/55842.html" rel="external">
          image 4A-B
         </a>
         ). The presentation, diagnosis, and treatment of patients with Pancoast syndrome due to superior sulcus tumors is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4605.html" rel="external">
          "Superior pulmonary sulcus (Pancoast) tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          CLINICAL MANIFESTATIONS OF EXTRATHORACIC METASTASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung cancer can spread to any part of the body. Metastatic spread may result in the presenting symptoms or may occur later in the course of disease.
        </p>
        <p>
         The staging at presentation of patients with known or suspected lung cancer is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4602.html" rel="external">
          "Tumor, node, metastasis (TNM) staging system for lung cancer"
         </a>
         .)
        </p>
        <p>
         The most frequent sites of distant metastasis are the liver, adrenal glands, bones, and brain.
        </p>
        <p class="headingAnchor" id="H355282319">
         <span class="h2">
          Bone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metastasis from lung cancer to bone is frequently symptomatic. Pain in the back, chest, or extremity and elevated levels of serum alkaline phosphatase are usually present in patients who have bone metastasis. The serum calcium may be elevated due to extensive bone disease. Approximately 20 percent of patients with NSCLC have bone metastases on presentation [
         <a href="#rid22">
          22
         </a>
         ]. An osteolytic radiographic appearance is more frequent than an osteoblastic one, and the most common sites of involvement are the vertebral bodies  (
         <a class="graphic graphic_diagnosticimage graphicRef73034" href="/z/d/graphic/73034.html" rel="external">
          image 5
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef76532" href="/z/d/graphic/76532.html" rel="external">
          image 6
         </a>
         ). Bone metastases are even more frequent in SCLC and can be found in 30 to 40 percent of patients [
         <a href="#rid23">
          23
         </a>
         ]. Positron emission tomography (PET) and integrated PET with computed tomography(CT; PET-CT) have improved the ability to identify metastases to many organs, including bone, with greater sensitivity than CT or bone scan [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer", section on 'Clinical-directed imaging'
         </a>
         .)
        </p>
        <p>
         The use of osteoclast inhibitors in patients with bone metastases from solid tumors is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">
          "Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Indications for osteoclast inhibitor therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355282326">
         <span class="h2">
          Adrenal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The adrenal glands are a frequent site of metastasis, occurring in 40 percent in one autopsy series [
         <a href="#rid25">
          25
         </a>
         ], but such metastases are only rarely symptomatic. Occasionally, patients with an adrenal metastasis will have localized symptoms (eg, back or abdominal pain) if the tumor is large or rapidly growing or has caused a retroperitoneal hemorrhage [
         <a href="#rid26">
          26
         </a>
         ]. Adrenal metastases do not usually result in adrenal insufficiency unless both adrenal glands are significantly (&gt;90 percent) consumed by disease. In these rare instances, patients can present with loss of appetite, weight loss, nausea, abdominal pain, weakness, and electrolyte imbalances secondary to adrenal insufficiency.
        </p>
        <p>
         Concern about adrenal metastasis usually occurs when a unilateral mass is found by staging CT in a patient with a known or suspected lung cancer. Only a fraction of adrenal masses detected on staging scans represent metastasis. This was illustrated by a series of 330 patients with operable NSCLC, in which 32 (10 percent) had an isolated adrenal mass [
         <a href="#rid27">
          27
         </a>
         ]. Only 8 of these 32 (25 percent) were malignant, while the remainder had benign lesions (adenomas, nodular hyperplasia, hemorrhagic cysts). Conversely, a negative imaging study does not exclude adrenal metastases. A study of patients with SCLC found that 17 percent of adrenal biopsies showed metastatic involvement despite having a normal CT scan [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The lack of specificity of an initial CT identifying an adrenal mass creates a special problem in patients with an otherwise resectable lung cancer. In this situation, PET may be particularly useful in distinguishing a benign from malignant adrenal mass  (
         <a class="graphic graphic_figure graphicRef64673" href="/z/d/graphic/64673.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid29">
          29
         </a>
         ]. Other procedures that may be useful in excluding a metastasis include magnetic resonance imaging consistent with a benign adenoma or a negative needle biopsy. (See
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer", section on 'Clinical-directed imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355282333">
         <span class="h2">
          Brain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic manifestations of lung cancer include metastases and paraneoplastic syndromes. (See
         <a class="local">
          'Paraneoplastic phenomena'
         </a>
         below.)
        </p>
        <p>
         Symptoms from central nervous system metastasis are similar to those with other tumors and include headache, vomiting, visual field loss, hemiparesis, cranial nerve deficit, and seizures. (See
         <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of brain metastases"
         </a>
         .)
        </p>
        <p>
         In patients with NSCLC, the frequency of brain metastasis is greatest with adenocarcinoma and least with squamous cell carcinoma. The risk for brain metastasis increases with larger primary tumor size and the presence of regional node involvement  (
         <a class="graphic graphic_diagnosticimage graphicRef63227" href="/z/d/graphic/63227.html" rel="external">
          image 7
         </a>
         ) [
         <a href="#rid30">
          30
         </a>
         ]. For carefully selected patients, sequential resection may be feasible in cases that have operable NSCLC in the chest and a solitary brain metastasis. (See
         <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">
          "Overview of the treatment of brain metastases"
         </a>
         .)
        </p>
        <p>
         In patients with SCLC, metastasis to brain is present in approximately 20 to 30 percent of patients at presentation [
         <a href="#rid31">
          31
         </a>
         ]. Without prophylactic irradiation, relapse in the brain occurs in approximately one-half of patients within two years. Randomized trials have shown that the frequency of brain metastases can be significantly reduced with prophylactic cranial radiation. (See
         <a class="medical medical_review" href="/z/d/html/4631.html" rel="external">
          "Prophylactic cranial irradiation for patients with small cell lung cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H563068809">
         <span class="h2">
          Liver
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic hepatic metastases are uncommon early in the course of disease. Asymptomatic liver metastases may be detected at presentation by liver enzyme abnormalities, CT  (
         <a class="graphic graphic_diagnosticimage graphicRef58174" href="/z/d/graphic/58174.html" rel="external">
          image 8
         </a>
         ), or PET  (
         <a class="graphic graphic_diagnosticimage graphicRef69909" href="/z/d/graphic/69909.html" rel="external">
          image 9
         </a>
         ). Among patients with otherwise resectable NSCLC in the chest, CT evidence of liver metastasis has been identified in approximately 3 percent of cases [
         <a href="#rid32">
          32
         </a>
         ]. PET or integrated PET-CT identifies unsuspected metastases in the liver or adrenal glands in approximately 4 percent of patients [
         <a href="#rid33">
          33,34
         </a>
         ]. The incidence of liver metastases is much higher later in the course of the disease. Autopsy studies have shown that hepatic metastases are present in more than 50 percent of patients with either NSCLC or SCLC [
         <a href="#rid25">
          25,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer", section on 'Clinical-directed imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3136275230">
         <span class="h2">
          Constitutional symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with lung cancer may also present with nonspecific symptoms that suggest the presence of advanced-stage disease. These symptoms include but are not limited to weight loss, anorexia, weakness, and fatigue. Reports of presenting symptoms of lung cancer show considerable variability in frequency of symptoms; for example, weight loss has been reported in 0 to 68 percent of patients and weakness in 0 to 10 percent [
         <a href="#rid36">
          36
         </a>
         ]. One series of 3800 patients with lung cancer reported weight loss as a presenting symptom in only about 3 percent of patients, but patients experiencing it experienced a shortened survival relative to patients presenting with cough alone [
         <a href="#rid6">
          6
         </a>
         ]. Fatigue is a less common symptom at presentation with lung cancer and becomes more common among patients undergoing treatment for lung cancer.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          PARANEOPLASTIC PHENOMENA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic effects of tumor are remote effects that are not related to the direct invasion, obstruction, or metastasis.
        </p>
        <p class="headingAnchor" id="H355282340">
         <span class="h2">
          Hypercalcemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercalcemia in patients with lung cancer may arise from tumor secretion of parathyroid hormone-related protein, or less commonly from extensive bony metastases or primary hyperparathyroidism.
        </p>
        <p>
         Symptoms of hypercalcemia include anorexia, nausea, vomiting, constipation, lethargy, polyuria, polydipsia, and dehydration. Confusion and coma are late manifestations as are renal failure and nephrocalcinosis. (See
         <a class="medical medical_review" href="/z/d/html/832.html" rel="external">
          "Clinical manifestations of hypercalcemia"
         </a>
         .)
        </p>
        <p>
         Patients who are symptomatic from hypercalcemia, or have significantly elevated serum calcium levels, regardless of symptoms, require treatment that includes hydration and bisphosphonate [
         <a href="#rid37">
          37
         </a>
         ]. The treatment of hypercalcemia due to malignancy is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/842.html" rel="external">
          "Hypercalcemia of malignancy: Mechanisms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/850.html" rel="external">
          "Treatment of hypercalcemia"
         </a>
         .)
        </p>
        <p>
         In one study of 1149 consecutive lung cancers, 6 percent had hypercalcemia [
         <a href="#rid38">
          38
         </a>
         ]. Among those with hypercalcemia, squamous cell carcinoma, adenocarcinoma, and SCLC were responsible in 51, 22, and 15 percent of cases, respectively. Most patients with hypercalcemia have advanced disease (stage III or IV) and a limited survival [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/842.html" rel="external">
          "Hypercalcemia of malignancy: Mechanisms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355282374">
         <span class="h2">
          SIADH secretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is frequently caused by SCLC and results in hyponatremia. Approximately 10 percent of patients who have SCLC exhibit SIADH [
         <a href="#rid39">
          39,40
         </a>
         ]. SCLC accounts for approximately 75 percent of all malignancy-related occurrences of SIADH. (See
         <a class="medical medical_review" href="/z/d/html/2354.html" rel="external">
          "Diagnostic evaluation of adults with hyponatremia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">
          "Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"
         </a>
         .)
        </p>
        <p>
         The severity of symptoms is related to the degree of hyponatremia and the rapidity of the fall in serum sodium. Symptoms include anorexia, nausea, and vomiting. Cerebral edema can occur when the onset of hyponatremia is rapid. Symptoms caused by cerebral edema may include irritability, restlessness, personality changes, confusion, coma, seizures, and respiratory arrest. (See
         <a class="medical medical_review" href="/z/d/html/2287.html" rel="external">
          "Manifestations of hyponatremia and hypernatremia in adults", section on 'Hyponatremia'
         </a>
         .)
        </p>
        <p>
         The treatment of SIADH focuses on treating the malignancy. In the majority of patients with SCLC, the hyponatremia will resolve within weeks of starting chemotherapy. Chronic hyponatremia or that of unclear duration may be treated with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion to euvolemia, fluid restriction and
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         , or a vasopressin-receptor antagonist. Acute and severe hyponatremia may be carefully treated with hypertonic (3 percent) saline infusion for a correction of 1 to 2 mmol per liter per hour with a correction of not more than 8 to 10 mmol per liter in 24 hours [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2357.html" rel="external">
          "Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H355283224">
         <span class="h2">
          Neurologic syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung cancer is the most common cancer associated with paraneoplastic neurologic syndromes; typically, these are associated with SCLC. Paraneoplastic neurologic syndromes are thought to be immune mediated, and autoantibodies have been identified in a number of instances. The various neurologic paraneoplastic syndromes and their pathophysiology are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">
          "Overview of paraneoplastic syndromes of the nervous system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15837.html" rel="external">
          "Paraneoplastic visual syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15822.html" rel="external">
          "Paraneoplastic cerebellar degeneration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15861.html" rel="external">
          "Opsoclonus-myoclonus-ataxia syndrome"
         </a>
         .)
        </p>
        <p>
         These diverse neurologic manifestations include, but are not limited to, Lambert-Eaton myasthenic syndrome (LEMS), cerebellar ataxia, sensory neuropathy, limbic encephalitis, encephalomyelitis, autonomic neuropathy, retinopathy, and opsomyoclonus [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         The most common of these is LEMS, which may be seen in approximately 3 percent of patients with SCLC  (
         <a class="graphic graphic_waveform graphicRef62084" href="/z/d/graphic/62084.html" rel="external">
          waveform 1
         </a>
         ) [
         <a href="#rid43">
          43
         </a>
         ]. The neurologic symptoms of LEMS precede the diagnosis of SCLC in more than 80 percent of cases, often by months to years. (See
         <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5134.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Treatment and prognosis", section on 'Evaluation for malignancy'
         </a>
         .)
        </p>
        <p>
         As many as 70 percent of patients who have SCLC and an associated paraneoplastic neurologic syndrome have limited-stage disease [
         <a href="#rid44">
          44
         </a>
         ]. The finding of a paraneoplastic autoantibody in patients presenting with a neurologic syndrome should lead to an evaluation for malignancy. A computed tomography (CT) of the chest is indicated in current or former smokers who have a suspected paraneoplastic neurologic syndrome. If the CT of the chest is negative, then positron emission tomography (PET) may be useful in identifying the location of a neoplasm. Even subtle abnormalities of the lungs or mediastinum require biopsy in this situation  (
         <a class="graphic graphic_diagnosticimage graphicRef66186 graphicRef75243" href="/z/d/graphic/66186.html" rel="external">
          image 10A-B
         </a>
         ) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Paraneoplastic neurologic syndromes generally do not improve with immunosuppressive treatment. However, symptoms may stabilize with response of the underlying neoplasm to treatment. Exceptions include Lambert-Eaton myasthenic syndrome and opsoclonus-myoclonus syndrome; most patients may experience resolution or partial remission with immunosuppression and treatment of the cancer.
        </p>
        <p class="headingAnchor" id="H355282953">
         <span class="h2">
          Hematologic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of hematologic abnormalities are seen in patients with lung cancer. These include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia
         </strong>
         – Anemia is frequent in patients with lung cancer and can contribute to fatigue and dyspnea. As an example, in one series, 40 percent of untreated patients had a hemoglobin ≤12 g/dL, while the incidence of anemia was 80 percent in those on chemotherapy [
         <a href="#rid46">
          46
         </a>
         ]. Anemia may be due to any of a number of causes, including microangiopathic hemolytic anemia and anemia of chronic disease. (See
         <a class="medical medical_review" href="/z/d/html/7140.html" rel="external">
          "Causes of anemia in patients with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">
          "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Leukocytosis
         </strong>
         – In one series, tumor-associated leukocytosis was found in 15 percent of patients with lung cancer. Nearly all had NSCLC, and the leukocytosis was thought to be due to overproduction of granulocyte-colony stimulating factor [
         <a href="#rid47">
          47
         </a>
         ]. Leukocytosis in association with lung cancer is associated with a poor prognosis and has also been associated with hypercalcemia [
         <a href="#rid38">
          38,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia", section on 'Causes of neutrophilia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombocytosis
         </strong>
         – Thrombocytosis is common and may be present in as many as 14 percent of patients with lung cancer at presentation [
         <a href="#rid48">
          48
         </a>
         ]. Thrombocytosis at presentation has been identified as an independent predictor of shortened survival [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eosinophilia
         </strong>
         – Eosinophilia in tissue or blood is rare but has been reported in patients with large cell carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">
          "Eosinophil biology and causes of eosinophilia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypercoagulable disorders
         </strong>
         – A variety of hypercoagulable disorders have been associated with lung cancer and other malignancies. These hypercoagulable disorders include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Superficial thrombophlebitis (Trousseau syndrome)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Deep venous thrombosis and thromboembolism
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Disseminated intravascular coagulopathy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thrombotic microangiopathy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nonbacterial thrombotic endocarditis
        </p>
        <p>
        </p>
        <p>
         These complications and their management are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">
          "Risk and prevention of venous thromboembolism in adults with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91781.html" rel="external">
          "Nonbacterial thrombotic endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H546074770">
         <span class="h2">
          Hypertrophic osteoarthropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertrophic pulmonary osteoarthropathy (HPO) is defined by the presence of clubbing  (
         <a class="graphic graphic_picture graphicRef71809" href="/z/d/graphic/71809.html" rel="external">
          picture 3
         </a>
         ) and periosteal proliferation of the tubular bones associated with lung cancer or other lung disease. Clinically, HPO is characterized by a symmetrical, painful arthropathy and long-bone pain that usually involves the ankles, knees, wrists, and elbows. The metacarpal, metatarsal, and phalangeal bones may also be involved. (See
         <a class="medical medical_review" href="/z/d/html/5615.html" rel="external">
          "Malignancy and rheumatic disorders", section on 'Hypertrophic osteoarthropathy'
         </a>
         .)
        </p>
        <p>
         A radiograph of the long bones (ie, femur, tibia, and fibula) shows characteristic periosteal new bone formation in patients with HPO. An isotope bone scan or PET typically demonstrates diffuse uptake by the long bones  (
         <a class="graphic graphic_diagnosticimage graphicRef62962 graphicRef72455" href="/z/d/graphic/62962.html" rel="external">
          image 11A-B
         </a>
         ). The symptoms of HPO may resolve after tumor resection. For patients who are not operable, the usual treatment is with nonsteroidal anti-inflammatory agents, corticosteroids, or a bisphosphonate [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H546074780">
         <span class="h2">
          Dermatomyositis and polymyositis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermatomyositis and polymyositis are two distinct forms of inflammatory myopathy, both of which are manifested clinically by muscle weakness. These inflammatory myopathies can be the presenting symptom in patients with lung cancer or can develop later in the course of disease. In addition to lung cancer, other frequent primary sites associated with these disorders include the ovary, cervix, pancreas, bladder, and stomach. The incidence of malignancy and the role of screening for cancer in patients with dermatomyositis or polymyositis are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5162.html" rel="external">
          "Malignancy in dermatomyositis and polymyositis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H546074787">
         <span class="h2">
          Cushing syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ectopic production of adrenal corticotropin can cause Cushing syndrome. Patients typically present with muscle weakness, weight gain, hypertension, hirsutism, and osteoporosis. However, when Cushing syndrome is due to SCLC, weight loss is more often present [
         <a href="#rid51">
          51
         </a>
         ]. Hypokalemic alkalosis and hyperglycemia are usually present. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
         Cushing syndrome is rare, but is most commonly seen in patients with SCLC, large cell neuroendocrine carcinoma, or carcinoid tumors of the lung [
         <a href="#rid52">
          52
         </a>
         ]. Patients with Cushing syndrome and SCLC appear to have a worse prognosis than patients with SCLC without Cushing syndrome [
         <a href="#rid52">
          52-54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4883.html" rel="external">
          "Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging", section on 'Cushing's syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H629783270">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15416.html" rel="external">
          "Patient education: Lung cancer (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/83057.html" rel="external">
          "Patient education: Asbestos exposure (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/891.html" rel="external">
          "Patient education: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         – Lung cancer is the most common cause of cancer mortality worldwide for both men and women. The majority of patients are symptomatic at presentation, although screening for lung cancer has been shown to save lives by detecting lung cancer in asymptomatic individuals at high risk. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">
          "Screening for lung cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrathoracic versus extrathoracic manifestations
         </strong>
         – The clinical manifestations of lung cancer can be due to intrathoracic effects of the tumor (eg, cough, hemoptysis, pleural disease), extrathoracic metastases (most commonly, liver, bone, brain), or paraneoplastic phenomena (eg, hypercalcemia, Cushing syndrome, hypercoagulability disorders, various neurologic syndromes). (See
         <a class="local">
          'Intrathoracic clinical manifestations'
         </a>
         above and
         <a class="local">
          'Clinical manifestations of extrathoracic metastases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrathoracic manifestations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cough
         </strong>
         – The new onset of cough in a smoker or former smoker should raise suspicion for lung cancer. Cough is present in 50 to 75 percent of lung cancer patients at presentation and occurs most frequently in patients with squamous cell and small cell carcinomas because of their tendency to involve central airways. (See
         <a class="local">
          'Cough'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Shortness of breath
         </strong>
         – Shortness of breath is a common symptom in patients with lung cancer at the time of diagnosis, occurring in approximately 25 to 40 percent of cases. Dyspnea may be due to extrinsic or intraluminal airway obstruction, obstructive pneumonitis or atelectasis, lymphangitic tumor spread, tumor emboli, pneumothorax, pleural effusion, or pericardial effusion with tamponade. (See
         <a class="local">
          'Chest pain'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extrathoracic manifestations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bone
         </strong>
         – Metastasis from lung cancer to bone is frequently symptomatic. Pain in the back, chest, or extremity, and elevated levels of serum alkaline phosphatase are usually present in patients who have bone metastasis. The serum calcium may be elevated due to extensive bone disease. Approximately 20 percent of patients with non-small cell lung cancer have bone metastases on presentation. (See
         <a class="local">
          'Bone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Central nervous system
         </strong>
         – Symptoms from central nervous system metastasis are similar to those with other tumors and include headache, vomiting, visual field loss, hemiparesis, cranial nerve deficit, and seizures. (See
         <a class="local">
          'Brain'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypercalcemia
         </strong>
         – Hypercalcemia in patients with lung cancer may arise from tumor secretion of parathyroid hormone-related protein or, less commonly, from extensive bony metastases. (See
         <a class="local">
          'Hypercalcemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Syndrome of inappropriate antidiuretic hormone secretion (SIADH
         </strong>
         ) – SIADH is frequently caused by small cell lung cancer (SCLC) and results in hyponatremia. Approximately 10 percent of patients who have SCLC exhibit SIADH. (See
         <a class="local">
          'SIADH secretion'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocher F, Hilbe W, Seeber A, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer 2015; 87:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974; 65:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athey VL, Walters SJ, Rogers TK. Symptoms at lung cancer diagnosis are associated with major differences in prognosis. Thorax 2018; 73:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colice GL. Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT. Chest 1997; 111:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo CW, Chen YM, Chao JY, et al. Non-small cell lung cancer in very young and very old patients. Chest 2000; 117:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piehler JM, Pairolero PC, Gracey DR, Bernatz PE. Unexplained diaphragmatic paralysis: a harbinger of malignant disease? J Thorac Cardiovasc Surg 1982; 84:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramadan HH, Wax MK, Avery S. Outcome and changing cause of unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 1998; 118:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen HC, Jen YM, Wang CH, et al. Etiology of vocal cord paralysis. ORL J Otorhinolaryngol Relat Spec 2007; 69:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decker DA, Dines DE, Payne WS, et al. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest 1978; 74:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts JR, Blum MG, Arildsen R, et al. Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer. Ann Thorac Surg 1999; 68:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985; 60:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maskell NA, Butland RJ, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003; 58 Suppl 2:ii8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swiderek J, Morcos S, Donthireddy V, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010; 137:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahman NM, Ali NJ, Brown G, et al. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahn SA. Malignancy metastatic to the pleura. Clin Chest Med 1998; 19:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. Eur J Radiol 2006; 59:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123:137S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenbygaard LE, Sørensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung--a study from a cohort of 259 consecutive patients treated with chemotherapy. Acta Oncol 1997; 36:301.
          </a>
         </li>
         <li class="breakAll">
          Cingam SR, Mukkamalla SKR, Karanchi H. StatPearls, StatPearls Publishing, Treasure Island (FL) 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver TW Jr, Bernardino ME, Miller JI, et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984; 153:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagani JJ. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. AJR Am J Roentgenol 1983; 140:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007; 242:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle TJ. Brain metastasis in the natural history of small-cell lung cancer: 1972-1979. Cancer 1982; 50:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 1994; 49:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007; 29:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jereczek B, Jassem J, Karnicka-Młodkowska H, et al. Autopsy findings in small cell lung cancer. Neoplasma 1996; 43:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiro SG, Gould MK, Colice GL, American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:149S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas L, Kwok Y, Edelman MJ. Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol 2004; 5:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiraki A, Ueoka H, Takata I, et al. Hypercalcemia-leukocytosis syndrome associated with lung cancer. Lung Cancer 2004; 43:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986; 4:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010; 68:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127:2331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosmidis P, Krzakowski M, ECAS Investigators. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 2005; 50:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasuga I, Makino S, Kiyokawa H, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001; 92:2399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax 2005; 60:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoe K, Hiraki A, Ueoka H, et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagy-Mignotte H, Shestaeva O, Vignoud L, et al. Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer. J Thorac Oncol 2014; 9:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delisle L, Boyer MJ, Warr D, et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993; 153:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd FA, Laskey J, Evans WK, et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 1992; 10:21.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4641 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33433946" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cancer Statistics, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25564398" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4813837" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical manifestations of lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2992757" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29666219" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Symptoms at lung cancer diagnosis are associated with major differences in prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9266882" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9106564" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10669674" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Non-small cell lung cancer in very young and very old patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6292583" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Unexplained diaphragmatic paralysis: a harbinger of malignant disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482553" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Outcome and changing cause of unilateral vocal cord paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264533" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Etiology of vocal cord paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/930945" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Carcinomatous involvement of the pleura: an analysis of 96 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/216532" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The significance of a cytologically negative pleural effusion in bronchogenic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10543472" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3974296" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12728146" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : BTS guidelines for the investigation of a unilateral pleural effusion in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19741064" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Prospective study to determine the volume of pleural fluid required to diagnose malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696694" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9646986" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Malignancy metastatic to the pleura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16476534" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12527573" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Noninvasive staging of non-small cell lung cancer: a review of the current evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11357499" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : FDG-PET imaging for the staging and follow-up of small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15140545" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9208901" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung--a study from a cohort of 259 consecutive patients treated with chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9208901" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung--a study from a cohort of 259 consecutive patients treated with chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6473783" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6301251" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9129444" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17229875" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6284340" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Brain metastasis in the natural history of small-cell lung cancer: 1972-1979.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8153934" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11978336" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17331966" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8843976" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Autopsy findings in small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17873166" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14697157" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Management of paraneoplastic syndromes in lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15165088" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hypercalcemia-leukocytosis syndrome associated with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3016206" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19535164" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17507705" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical practice. The syndrome of inappropriate antidiuresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17480225" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Paraneoplastic neurological syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1659614" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12111309" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15361417" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16191450" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11745296" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16227326" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15031573" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Thrombocytosis as a useful prognostic indicator in patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15293094" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24736072" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15914534" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8383484" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1309381" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
